Published on
30/06/2026 - 14:59 GMT+2
Paris-based biotechnology company Abivax, which develops treatments for chronic inflammatory diseases, saw its shares jump 36% on Tuesday after releasing new data on its lead drug candidate, obefazimod.
The latest results from the maintenance phase of its Phase 3 ABTECT trial showed the experimental oral treatment provided“clinically meaningful improvements” for adults with moderate to severe ulcerative colitis, including patients whose disease had previously failed to respond to treatment.
After 44 weeks, 37.2% of patients who had not responded during the initial treatment phase achieved clinical remission, meaning their symptoms had largely disappeared, while 34.5% showed healing of the bowel lining.
